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IMPORTANCE Several trials demonstrated the impact of novel agent-based maintenance in
newly diagnosed multiple myeloma (NDMM), but there is no current evidence demonstrating
the superiority of one regimen over the other, owing to the lack of direct/indirect comparisons.
OBJECTIVE To analyze and compare the effectiveness of different maintenance regimens in
NDMM via a network meta-analysis.
DATA SOURCES We performed 2 independent searches in PubMed and Cochrane databases,
and then we identified all the records registered after 1999 and on or before November 20, 2017.
STUDY SELECTION By blinded review, we identified prospective phase 3 randomized trials
evaluating novel agent-based maintenance in patients with NDMM; the included studies
compared at least 2 maintenance approaches; comparators included placebo and no
maintenance. From 364 screened records, 11 studies were included.
DATA EXTRACTION AND SYNTHESIS We followed (independent extraction) the guidelines
provided by the PRISMA Report and the EQUATOR Network. The evidence was synthesized
using a network meta-analysis (NMA). To allow comparison of all treatments, no maintenance
was selected as common comparator and the effect of placebo was assumed to be the same
as no treatment. The best option was identified by a Bayesian consistency model based on
hazard ratio (HR), 95% credible interval (CrI), probability of being the best treatment (PbBT),
and median ranking distribution (MedR).
MAIN OUTCOMES AND MEASURES Outcomes of interest were progression-free survival (PFS)
and overall survival (OS).
RESULTS Eleven trials and 8 treatments including a total of 5073 participants were included.
By PFS analysis, lenalidomide-based regimens (lenalidomide-prednisone, lenalidomide alone)
were identified as the most effective options (HR, 0.39 [95% CrI, 0.28-0.53] and 0.47 [95%
CrI, 0.39-0.55], respectively; MedR, 1 and 2; overall PbBT, 74%). Four treatments
(thalidomide-interferon, thalidomide-bortezomib, bortezomib-prednisone, thalidomide
alone) showed an HR in favor of maintenance. By OS analysis, lenalidomide alone was
identified as the best option (HR, 0.76; 95% CrI, 0.51-1.16; MedR, 2; PbBT, 38%), followed by
bortezomib-thalidomide and bortezomib-prednisone. Similar features were noticed in the
restricted network including transplant trials, in the sensitivity analysis, and in most of the
prognostic subgroups.
CONCLUSIONS AND RELEVANCE Based on PFS and OS results of this NMA, lenalidomide
maintenance appears to be the best treatment option, by synthesizing the available evidence
of novel agent-based maintenance in the past 20 years.
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T he continuous therapy (CT) approach has been evalu-ated extensively in patients with newly diagnosed mul-tiple myeloma (NDMM), across age groups and treat-
ment strategies upfront, in several trials with different designs.
It generally consists of multiagent chemotherapy for a fixed
time, followed by a less intensive but prolonged maintenance
treatment. Some trials showed the benefit of thalidomide con-
tinuous therapy in terms of progression-free survival (PFS),
with inconsistent results for overall survival (OS).1-10 The ef-
ficacy of continuous thalidomide is compromised by its poor
tolerability, with peripheral neuropathy mainly limiting the
long-term use. In a trial randomizing patients to bortezomib-
based induction, autologous stem cell transplantation (ASCT)
and bortezomib maintenance vs vincristine-doxorubicin-
dexamethasone induction, ASCT and thalidomide mainte-
nance, bortezomib-based therapy prolonged PFS, with a bet-
ter safety profile.11,12 Bortezomib-thalidomide maintenance
has also been evaluated both in the nontransplant and trans-
plant settings.13-17 A meta-analysis showed improved PFS as
well as OS with lenalidomide maintenance vs no maintenance/
placebo in the posttransplant setting.18 Recent data from the
Myeloma XI trial confirmed these findings.19
Despite the well-recognized importance of maintenance,
there is no evidence demonstrating the overall superiority
of 1 regimen over the others, owing to the lack of direct or in-
direct comparisons. Furthermore, there are several well-
known factors that may affect outcome, such as baseline prog-
nostic features (International Staging System [ISS] Stage20
and chromosomal abnormalities21). Direct comparisons in
specific patient subsets are lacking as well.
We performed a systematic literature review to identify the
randomized clinical trials (RCTs) in NDMM evaluating main-
tenance treatments using novel agents and then a network
meta-analysis (NMA) to synthesize the efficacy (PFS, OS) of
each regimen over the others. To do this, we collected and,
whenever necessary, reanalyzed the data of each study in-
cluded in the network. Our main goal was to compare the
efficacy of each treatment vs no maintenance/placebo over-
all and in specific patient subgroups.
Methods
Systematic Literature Review and Studies Selection
This meta-analysis adheres to the guidelines provided by the
PRISMA report and the EQUATOR Network.22,23 We per-
formed 2 independent searches (F.G. and U.P.) in the data-
bases PubMed and Cochrane Central Register of Controlled Trials
using the search terms “myeloma” and “maintenance.” We
excluded records registered before December 31, 1999, be-
cause our aim was to focus on novel agents only. The entire
search had a cut-off date of November 20, 2017, and was re-
stricted to articles in English. To ensure that no RCTs were miss-
ing, we also considered additional sources (eAppendix in the
Supplement), which were added manually to the PRISMA
Flowchart (Figure 1).
Eligibility criteria were defined in terms of population,
interventions, comparisons, outcomes, and study design
(PICOS) criteria.22 The study population of interest com-
prised NDMM patients; the studies included are prospective
phase 3 RCTs that compared at least 2 maintenance ap-
proaches; maintenance treatments should include 1 or more
novel agents (thalidomide, lenalidomide, bortezomib) in at
least 1 arm; comparators included placebo and no mainte-
nance. To specifically evaluate the impact of maintenance, we
excluded trials in which patients who received 2 different main-
tenance treatments underwent different and noncomparable
Figure 1. PRISMA Flowchart
1386 Records identified through
database searching
(Dec 31, 1999-Nov 20, 2017)
8 Additional records identified
through other sources
1264 Records after duplicates removed
364 Records screened
62 Full-text articles assessed for eligibility
11 Studies included in qualitative synthesis













302 Full-text articles excluded
197 Study design
3 No data available
53 Study phase
38 Patient population
11 No translation available
Key Points
Question What is the current best maintenance approach in
patients with myeloma?
Findings This network meta-analysis included 11 trials and
8 treatments including a total of 5073 participants and found that
6 maintenance treatments prolonged progression-free survival vs
no maintenance: lenalidomide-based regimens were identified as
the most effective options. On overall survival analysis,
lenalidomide alone was identified as the best option; similar
features were noticed in the restricted network including
transplant trials, in the sensitivity analysis, and in most of the
prognostic subgroups.
Meaning By synthesizing the available evidence of novel agent-based
maintenance in the last 20 years, lenalidomide maintenance can be
currently considered the best treatment option.
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premaintenance therapies (no stratification according to in-
duction at the time of maintenance randomization) because
in such trials the final outcomes could be related to the com-
bined effect of both induction and maintenance. To analyze
the impact of maintenance in the context of a current treat-
ment approach, we excluded maintenance trials that en-
rolled only patients who did not receive novel agents during
induction because this is no longer a standard approach. Nev-
ertheless, these trials were subsequently included in a sensi-
tivity analysis. Outcomes of interest included PFS and OS.
After removing duplicates by blinded review, titles and ab-
stracts of the citations were screened for inclusion using
Excel (version 2013, Microsoft Corporation) and then full-
text articles were examined to assess suitability.
The Cochrane Collaboration’s tool for assessing risk of bias
in RCTs was used.24 Risks of bias were assessed indepen-
dently by 2 reviewers (F.G. and S.S.); when data were not re-
ported in the main publications, we asked authors of the dif-
ferent articles to provide them (eAppendix in the Supplement).
Data Extraction
Data were independently extracted from all eligible RCTs that
reported hazard ratios (HRs) and confidence intervals (CIs) for
PFS and/or OS, or provided data to estimate HRs and CIs in case
the study did not report these parameters. Where not avail-
able, the HR was estimated using the ratio between probabili-
ties and the 95% CI was estimated using the P value (eAppen-
dix in the Supplement).25
The HRs and P values for PFS and OS were collected for the
main comparison (all patients included in the main analysis).
We performed a restricted analysis of PFS and OS in patients pre-
viously treated with ASCT; in this analysis, for trials enrolling
both patients who had received ASCT and not, only 95% CI and
HR of the subgroup of ASCT patients were included.
Subgroupanalysesaccordingtoprognosticfeatureswereper-
formed. For these analyses, we included only studies with avail-
able data on both ISS stage and cytogenetic risk. The HRs and
P values for PFS were collected for the subsequent subsets:
ISS stages I/II, ISS stage III; high-risk chromosomal abnormali-
ties detected by FISH (del(17p) and/or t(14;14) and/or t(14;16)),
standard-risk (absence of del(17p), t(14;14), t(14;16)). For these
subgroup analyses we focused on PFS only owing to the small
number of patients in each subgroup, which could be a limita-
tion, even more relevant in the OS analysis, given the lower num-
ber of events. Whenever data were either unavailable in the
full-text articles, or noncomparable owing to different risk cat-
egorization, these were provided by the cooperative groups.
Network Meta-analysis
The NMA was conducted using the natural log transforma-
tions of HRs, and their 95% CIs to estimate standard errors (SEs).
To include all trials within 1 framework, we had to choose
a common comparator, and we chose no maintenance/
placebo. We assumed that placebo treatment was equivalent
to no maintenance and that there were no differences in effi-
cacy due to dosages or schemes (for thalidomide, lenalidomide,
lenalidomide-prednisone, and bortezomib-thalidomide).
We used the R-Project statistical software (version 3.1.1,
R Foundation) and the gemtc and R2WinBUGS statistical pack-
ages to perform the analysis with WinBugs (version 14, The
BUGS Project). Because no loop or design inconsistencies were
present, the NMA was conducted following the Bayesian con-
sistency framework.26
The simulation was performed using the Markov Chain
Monte Carlo (MCMC) technique with 3 different chains, and
each of them produced 500 000 interactions with 300 000
burn-in samples and 15 thinning rates. The output of Bayesian
NMA is a posterior distribution of relative effect size, and we
obtained the HR as a mean value, and 95% credible interval
(95% CrI) as the 2.5th and 97.5th percentiles. Subsequent to
performing all the simulations, we calculated the percentage
of simulations in which every single treatment ranked first to
determine its probability of being the best treatment (PbBT).
For each treatment, we estimated the median value of the rank-
ing distribution for all the simulations (MedR). This allowed
us to consider not only when a treatment ranked first, but also
any other ranking it could obtain. The best option was iden-
tified on the basis of MedR, HR with 95% CrI, and PbBT.
Results
Study Selection
Sixty-two publications were included, corresponding to 11 trials
(Figure 1) (eAppendix in the Supplement).
All trials started enrollment after 2001, 4 trials enrolled
only patients ineligible for ASCT, 4 trials included both
patients eligible and not eligible for ASCT, and 3 trials
enrolled only patients eligible for ASCT. Eight maintenance
options were evaluated: no maintenance/placebo, inter-
feron, thalidomide alone, thalidomide-bortezomib,
thalidomide-interferon, lenalidomide alone, lenalidomide-
prednisone, and bortezomib-prednisone. eTable 1S in
the Supplement summarizes the main characteristics of
the included trials and each maintenance treatment
schedule.13,16-19,27-37 Overall, the included trials presented
minimal risk of bias (eAppendix in the Supplement).
Primary Analysis: PFS and OS
With Different Maintenance Strategies
The primary analysis network was composed of all the
selected trials (5073 patients) (Figure 2). On PFS analysis, le-
nalidomide-based regimens had the most favorable HR
(lenalidomide-prednisone HR, 0.39 [95% CrI, 0.28-0.53];
lenalidomide alone HR, 0.47 [95% CrI, 0.39-0.55]); they ranked,
on median, first and second in all the simulations; overall, they
resulted in the most effective options in 74% of the simula-
tions. Four treatments (thalidomide-interferon, thalidomide-
bortezomib, bortezomib-prednisone, thalidomide alone)
showed an HR in favor of maintenance (HR range, 0.50-0.73);
only 1 (interferon) did not show any benefit. On OS analysis,
lenalidomide alone was identified as the best option, based
again on HR, MedR, and PbBT, followed by thalidomide-
bortezomib and bortezomib-prednisone. No benefit was
suggested with the other regimens (Figure 3) (eFigure 1S in
the Supplement).
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IFN, interferon; Len, lenalidomide;
Bort, bortezomib; Pred, prednisone.










70 1Len-Pred 0.39 (0.28-0.53) 
4 2Len 0.47 (0.39-0.55) 
22 3Thal-IFN 0.50 (0.25-1.02) 
3 4Thal-Bort 0.58 (0.35-0.95) 
1 5Bort-Pred 0.72 (0.40-1.27) 
0 5Thal 0.73 (0.53-1.00) 
0 7IFN 0.91 (0.55-1.51) 











8 5Len-Pred 0.98 (0.50-2.03) 
38 2Len 0.76 (0.51-1.16) 
9 7Thal-IFN 1.22 (0.33-4.53) 
21 3Thal-Bort 0.82 (0.30-2.20) 
21 3Bort-Pred 0.84 (0.25-2.80) 
2 5Thal 1.04 (0.53-2.12) 
1 7IFN 1.31 (0.50-3.53) 
1 5No maintenance/placebo 1.00
Overall survivalB
Thal indicates thalidomide;
IFN, interferon; Len, lenalidomide;
Bort, bortezomib; Pred, prednisone;
PFS, progression-free survival;
OS, overall survival; PbBT, probability
of being the best treatment;
MedR, median value of the ranking
distribution for all the simulations.
A, PFS results. B, OS results.
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Restricted Analysis: PFS and OS in the ASCT Setting
Seven trials (Myeloma IX, CALGB-100104, IFM-2005-02, RV-
MM-PI-209, RV-MM-EMN-441, Myeloma XI, GEM05MENOS65)
were included (2917 patients) (eFigure 2S, eTable 4S in the
Supplement).
Results were similar to those of the primary analysis net-
work. Regarding PFS, lenalidomide-based maintenance regi-
mens were identified as the best options; thalidomide-
bortezomib and Thal showed a HR in favor of maintenance
(HR range, 0.58-0.73), and no benefit was noticed with inter-
feron. On OS analysis, lenalidomide-based regimens were the
best option; no benefit with any other regimen was noticed
(eFigure 2S in the Supplement; panels B and C).
Subgroup Analyses: Prognostic Features
Eight trials (NCT00205751, Myeloma IX, IFM-2005-02, 2005-
001111-21, RV-MM-PI-209, RV-MM-EMN-441, GEM05MENOS65,
EMN-01) were included in the subgroup analysis (eFigure 3S and
eTable 5S in the Supplement). Two trials were excluded (CALGB
100104, MM-015) because no data on cytogenetic abnormalities
were available; 1 trial (Myeloma XI) was not included because
the publication of the main article is still underway.
Results of the subgroup analysis in patients with good prog-
nosis (ISS stage I or II disease [n = 2144] and standard-risk chro-
mosomal abnormalities [n = 1657]) suggested lenalidomide-
based maintenance as the best option in this subset, on the
basis of HR, MedR, and PbBT. Subgroup analysis on patients with
poor prognosis, although limited by a lower sample size, sug-
gested a major benefit of bortezomib-based maintenance in
patients with ISS stage III disease (n = 626), but failed to detect
the advantage of any regimen over no maintenance/placebo in
patients with high-risk chromosomal abnormalities (n = 392)
(eFigure 4S in the Supplement).
Sensitivity Analyses
A sensitivity analysis was conducted on a slightly broader net-
work of 14 trials (6516 patients) (eFigure 5S in the Supple-
ment). This analysis added to the primary analysis 3 trials
(IFM9902, MY10 and ALLG MM6) and 3 maintenance options
(thalidomide-pamidronate, thalidomide-prednisone, and
prednisone)8-10 in a population of patients not previously
exposed to novel agents. Results of the analysis for PFS sug-
gested lenalidomide-based therapies as the best option. In terms
of OS, the trend was again similar to that of the main analysis,
except for the OS advantage with thalidomide-pamidronate.
Discussion
Maintenance treatment is defined as any therapy adminis-
tered after the completion of the induction period in patients
either responsive or nonprogressive, with the goal of prolong-
ing survival.38,39 The optimal maintenance therapy should be
a convenient treatment, with a good compliance and toler-
ability. In the past 20 years, several trials have evaluated main-
tenance with either 1 or more of these drugs. Most trials showed
the benefit of long-term novel agent-based treatment in
both young, ASCT-eligible patients, and elderly patients.
Nevertheless, direct comparisons of such regimens are lack-
ing, and it is hard to draw conclusions.
The primary objective of this meta-analysis was to
synthetize all the available evidence on maintenance with
thalidomide, bortezomib, and lenalidomide in NDMM (ASCT
and non-ASCT settings) and to contribute to identifying the best
maintenance approach. We used HRs as effect measure for sur-
vival and included all the treatments evaluated during the last
20 years into a single network, including the most recently pub-
lished studies. To enable the comparison, we had to arbi-
trarily choose a common comparator, and we opted for no
maintenance/placebo.
Results of analysis suggested that lenalidomide was the
best maintenance option. Lenalidomide and lenalidomide-
prednisone were associated with the best PFS advantage.
Lenalidomide alone was associated with the best OS advan-
tage. This is not surprising: first, 5 randomized trials showed
a significant PFS advantage with lenalidomide alone vs no
maintenance/placebo19,30-32,40,41; second, a recent meta-
analysis demonstrated a significant OS advantage of lenalido-
mide alone vs no maintenance/placebo in the post-ASCT
setting18; and third, 2 trials showed a moderate PFS benefit
adding prednisone to lenalidomide vs lenalidomide alone, but
no OS advantage.35-37
Use of thalidomide-interferon, thalidomide alone, tha-
lidomide-bortezomib, and bortezomib-prednisone showed an
HR for PFS in favor of maintenance but no OS benefit. Unlike
lenalidomide alone, all these regimens were evaluated in a
single trial each; their estimated lower effectiveness was there-
fore based on single-trial results, which could be a limitation.
Long-term use of lenalidomide undoubtedly has advan-
tages, owing to the lack of neuropathy, which is the main fac-
tor limiting the long-term use of both thalidomide and
bortezomib. The main toxic effects associated with lenalido-
mide maintenance include neutropenia, thrombocytopenia,
cutaneous eruption and, in the long term, diarrhea.
Use of interferon alone showed no PFS or OS benefit in com-
parison with no maintenance/placebo. These results are in con-
trast to some previous studies42-44 conducted in the prenovel
agent era, and could be partly related to a stronger effect of
interferon in patients not previously exposed to novel drugs.
Results of our main analysis were confirmed in the post-
ASCT setting, supporting the recent approval of the drug by
the US Food and Drug Administration and the European
Medicines Agency in this setting.
Yet, it remains to be defined as to whether all patients re-
quire maintenance therapy or not or, most importantly, if the
choice of the agent/s should be dictated by disease character-
istics. The benefit of lenalidomide in high-risk patients is still a
matter of debate, based on conflicting results of published stud-
ies, and on the potentially higher effectiveness of bortezomib
in this setting. Sub-analyses of several trials30,32,34,35 sug-
gested the suboptimal efficacy of lenalidomide alone in high-
risk patients, but recent results of the Myeloma XI trial did show
a benefit also in high-risk disease19; yet, patients who received
lenalidomide maintenance in the Myeloma XI trial were previ-
ously treated with IMiDs and were sensitive to the drug. Vari-
ous studies showed the efficacy of bortezomib in high-risk
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patients11,12,14,15,45; nevertheless, this was associated more of-
ten with a bortezomib-based induction and consolidation/
maintenance rather than with maintenance itself. Updated re-
sults of the HOVON-65/GMMG-HD4 trial suggested that the
negative effect of del17 was abrogated by bortezomib-based
induction and maintenance, whereas there was only a trend for
improved OS in patients with t(4;14) and 1q gain.12 A recent ret-
rospective comparison of bortezomib vs lenalidomide therapy
in elderly patients suggested an advantage of bortezomib
upfront in patients with either del17, t(4;14) or t(14;16).46 Again,
head-to-head comparisons in specific subgroups are lacking.
To our knowledge, this is the first NMA to evaluate which drug
isassociatedwithbestresultsformaintenancetherapyinpatients
with different prognostic features. Patients with good prognosis
(ISSstagesIandIIandstandard-riskchromosomalabnormalities)
highly benefit from maintenance, and lenalidomide-based
therapy was associated with the best outcomes in this subset.
Subgroup analyses in high-risk patients are limited by the lower
number of patients. Despite these low numbers, bortezomib-
based maintenance seems to be more beneficial for patients with
ISS stage III disease. No specific advantage of any maintenance
overtheotherwasnoticedinpatientswithhigh-riskchromosomal
abnormalities. It remains uncertain as to whether this is related
to the small sample size, the different cut-off used to define posi-
tivity, or the extremely poor prognosis of these patients. Consid-
eringthepoorprognosisrelatedtothesechromosomalabnormali-
ties, the conflicting RCT results on the efficacy of lenalidomide
alone, the absence of clear advantage of 1 agent over the other,
and the retrospective nature of this analysis, we cannot conclude
that lenalidomide alone is sufficient for high-risk patients and a
better choice would probably be to combine lenalidomide with
proteasome inhibitors, instead of using only 1 agent.47
Assumptions and Limitations
To perform this NMA and include all trials in the same net-
work, we made 2 assumptions. The first is that the effect of
placebo was the same as no maintenance. Trials using pla-
cebo as control vs observation have the advantage of reduc-
ing bias in reporting quality of life and in grading adverse events
(such as anxiety, fatigue, pain), whereas knowing or not know-
ing which participants are receiving therapy may partially affect
subjective evaluation. Nevertheless, the main aims of our
analysis were PFS and OS; events like progression and death
are not influenced by the use of placebo or simple observa-
tion, therefore we believe that the assumption that placebo is
equivalent to no maintenance can be acceptable for this type
of analysis. Of note, only 3 trials included in our NMA used pla-
cebo, and they all evaluated lenalidomide maintenance; the
estimation of the effect of lenalidomide maintenance therapy
is based on 5 trials and this further minimizes the risk of bias.
The second assumption is that different thalidomide doses
(50-200 mg), lenalidomide schedules (28 days continuously
or 21/28 days), and prednisone doses (50-25 mg) had an equiva-
lent effect. Although this latter assumption might be a limita-
tion, there are data suggesting similar survival in patients ran-
domized to different thalidomide doses48; likewise, slightly
different schedules of lenalidomide maintenance therapy in-
duced similar median PFS31-34; in the EMN441 trial, 50 mg of
prednisone was not well tolerated in the long term, and me-
dian time to dose reductions (25 mg) was 6 months; thereaf-
ter prednisone could be administered for a longer time, thus
making similar the dose administered in the 2 trials.35
We excluded from this NMA trials that evaluated continu-
ous therapy upfront but administered 2 different mainte-
nance treatments after different and noncomparable premain-
tenance therapies because in such trials the final outcome was
probably related to the combined effect of both induction and
maintenance, rather than the maintenance therapy itself. The
impact of some of these continuous approaches has been evalu-
ated in 2 NMAs, which reported a PFS and OS advantage of
lenalidomide-dexamethasone (Rd) over the other therapies,
including MPT and VMP (fixed duration) in elderly patients.49,50
More recently, Bort-Rd for 8 cycles, followed by continuous Rd
showed better PFS and OS vs continuous Rd alone in patients
without an immediate intent to undergo ASCT.51 In the
transplant setting, randomized clinical trials showed the
efficacy of long-term thalidomide7,52 (but mainly compared
with a treatment not including any novel agent) and the su-
periority of Bort-based pretransplant induction followed by
bortezomib maintenance therapy over vincristine-doxorubicin-
dexamethasone pretransplant induction followed by thalido-
mide maintenance therapy.11,12
To analyze the impact of maintenance therapy in the con-
text of current treatment approaches, we excluded from our
primary analysis 3 trials8-10 that evaluated thalidomide main-
tenance therapy post-ASCT in patients who did not receive
novel agents-based induction. Because this could be a limita-
tion, these trials were subsequently included in a sensitivity
analysis, which had similar PFS results to the main analysis;
an unexpected OS advantage was noticed with thalidomide-
pamidronate. This could at least in part be related to the esti-
mation required to calculate the HR, and/or to a stronger ef-
fect of thalidomide in patients not previously treated with novel
drugs. An advantage in favor of thalidomide-based mainte-
nance therapy was not evident in the other trials.
We did not report on adverse events, drug discontinua-
tions, and quality of life because our main objectives were PFS
and OS. In addition, because we used no treatment as com-
mon comparator, data on adverse events, discontinuations, and
quality of life were not available and the comparison across
trials was possible. These are indeed key factors: the oral ad-
ministration, good tolerability, and no worsening in quality of
life53 support the use of lenalidomide for most patients in the
context of the currently available drugs. An increase in sec-
ond primary malignant disease with prolonged lenalidomide
therapy has been reported,31-33,54 but the survival benefit over-
came the risk in all the trials. The optimal dose (10 vs 15 mg)
and schedule (21/28 days or continuously) are still open is-
sues. Main grade 3 to 4 nonhematologic toxic effects were
similar in patients treated with different doses and schedules
in the trials evaluating lenalidomide maintenance therapy
post-ASCT, but both grade 3 and 4 neutropenia and thrombo-
cytopenia were lower in patients treated with 10 mg 21/28 days
compared with 10-mg escalated to 15 mg and administered
continuously.31-34 The optimal duration is still to be deter-
mined. Some trials evaluated maintenance therapy until
Research Original Investigation Maintenance Treatment and Survival in Patients With Myeloma
1394 JAMA Oncology October 2018 Volume 4, Number 10 (Reprinted) jamaoncology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a USAL User  on 06/01/2021
progression, others for up to 2 to 3 years, but no randomized clini-
cal trial addressed so far the benefit of treatment until progres-
sion vs 2 to 3 years. Because of toxicity, thalidomide could be
often administered only for a few months and bortezomib ad-
ministrationwasplannedforamaximumof2to3years.Although
lenalidomide therapy was planned in most of the studies as treat-
ment until progression, the mean duration of treatment was ap-
proximately30months.18 Durationoftherapyisthereforestrictly
related to tolerability, and most of the trials showed that the ef-
fective duration of maintenance therapy is limited to 2 to 3 years.
Another unanswered question is the benefit of upfront continu-
ous lenalidomide vs lenalidomide-containing triplets at first re-
lapse because there are no data available on the effectiveness
of the currently approved lenalidomide-containing triplets in
patients refractory to lenalidomide.
Conclusions
Despite the assumptions and limitations of this NMA, our re-
sults support the use of lenalidomide maintenance therapy in
most patients. Still, better treatment options are required in pa-
tients with aggressive disease, who may benefit from combi-
nations of proteasome inhibitors and immunomodulatory
agents. There are ongoing trials evaluating maintenance therapy
with second-generation proteasome inhibitors alone or plus im-
munomodulatory agents and with monoclonal antibodies.
These well-tolerated drugs, which could have a potential effi-
cacy in standard but also in high-risk disease, could become
available in the maintenance therapy setting in the near fu-
ture, and increase the treatment options for patients with MM.
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